<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, May 11, 2018 (HealthDay News) — Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up, according to a study published online May 7 in the Journal of Clinical Pharmacy and Therapeutics<\/i>.<\/p>\n
Thalia Medeiros, from the Universidade Federal Fluminense in Niter\u00f3i, Brazil, and colleagues evaluated renal biomarkers among 94 chronic hepatitis C patients treated with sofosbuvir therapy. Urine samples were collected at the end of therapy, after 12 weeks sustained virological response, and one year post-treatment.<\/p>\n
The researchers found that 98.9 percent of patients reached sustained virological response. In patients with glomerular filtration rate (GFR) \u226545 mL\/min\/1.73 m\u00b2 there was significant improvement in renal biomarkers, as indicated by a progressive increase in mean GFR values until one year. There was no evidence of tubular dysfunction. There was no change in renal biomarkers among patients with baseline GFR <45 mL\/min\/1.73 m\u00b2.<\/p>\n
“In a ‘real-life experience’ of a Brazilian center, sofosbuvir therapy appears to guarantee renal safety for patients with chronic hepatitis C followed until one year after treatment,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n